Paysign Inc. Q3 2026 Earnings Call - PAYSIGN INC

Explicit Guidance:

• Full-Year 2026 Revenue: Expected to conclude within the range of $114 million to $117 million.
• Full-Year 2026 Gross Profit Margins: Projected at 63.5% to 64.5%, driven by the increasing mix of higher-margin patient affordability revenue.
• Full-Year 2026 GAAP Net Income: Anticipated to be $23 million to $24 million, translating to $0.37 to $0.38 per diluted share.
• Full-Year 2026 Adjusted EBITDA: Forecasted between $38.5 million and $40 million.
• Full-Year 2026 Tax Rate: Expected to be approximately 21.3%.
• Q4 2026 Financial Impact: Anticipated revenue reduction of $1.5 million and gross profit reduction of $700,000 due to the transition of 113 plasma processing centers to a competitor.

Business-Segment Outlook:

• Patient Affordability (Pharma):
  • Program Count: Expect to end 2026 with 190 to 195 active programs, representing a net addition of 59 to 64 programs for the full year.
  • Growth Trajectory: Pipeline is described as "robust," supporting outlook through 2027. Program onboarding typically concentrates in the second half of the year (H2), as clients prepare for January 1st insurance resets; H1 2026 saw only 4 program additions.
  • Financial Metrics: Revenue per program increased 32% YoY to $99,524 in Q3, indicating deepening client relationships rather than just volume expansion.
• Plasma Business:
  • Center Count: Expects to exit 2026 servicing 445 to 450 centers (down from 562 at quarter-end), reflecting the 113-center transition.
  • Replacement Strategy: Confident in offsetting lost centers via new wins from existing clients and prospective collection companies over the "next couple of quarters"; actively in discussions with "a couple of prospective new plasma clients."
  • Efficiency: Centers are generating higher average monthly revenue per center ($8,187 in Q3 vs. $7,122 YoY).
• Aferion (SaaS):
  • Status: Donor management system under regulatory review; in-center testing completed.
  • Market Interest: Strong interest noted in both U.S. and EU markets; European base being built in Dublin via subsidiary Aferion Technologies Limited.
  • Commercial Outlook: Anticipates a "quicker ramp" in book-of-business building post-approval, leveraging pre-existing client conversations; no specific launch timeline provided.

Market and Competitive Outlook:

• Pharma Industry Dynamics: Value proposition resonating at senior levels regarding "copay maximizers and accumulators." Upcoming industry engagement includes the Informa Co-Pay Congress in November, where new 2027 service offerings will be announced.
• Plasma Market: Viewed as a mature, transactional market with limited growth; strategy involves targeting collection companies not currently using Paysign and leveraging "Ethereum" (likely typo in transcript for "Aferion") software to attract new centers.
• Competitive Shifts: One major customer consolidated banking/payment processing with an existing partner; management expects historical churn patterns where banks enter and exit, noting a lack of crystal-ball predictability but confidence in long-term competitiveness.
• Seasonality: Pharma business seasonality is currently masked by continuous program onboarding in Q3/Q4, counteracting typical claim volume drops in the latter half of the year.

Macro / Industry Outlook:

• Regulatory: Pending FDA approval for Aferion's donor management system; response to regulator questions is ongoing with no timeline for approval.
• Industry Trends: Rising industry awareness of cost-saving solutions for pharmaceutical manufacturers and patient outcomes is accelerating adoption of dynamic business rule technologies.
• Economic/Operational: No specific macroeconomic commentary provided, though management cites "operating leverage" and "strong utilization" as key drivers.

Strategic Initiatives:

• Product Expansion: Planned to launch 19 new programs in Q3 2026; total active programs to reach 190–195 by year-end.
• Geographic Expansion: Establishing a European footprint for Aferion in Dublin via a wholly-owned subsidiary.
• Technology Deployment: Dynamic Business Rules (DBR) technology continues to insulate clients from copay costs; cumulative savings surpassed $923 million since launch.
• Platform Diversification: Executing a dual-engine strategy pairing cash-generative plasma business with high-margin, fast-growing patient affordability business.

Risks and Headwinds to Outlook:

• Customer Concentration/Churn: Loss of 113 plasma centers (approx. $11.3M annualized revenue, $5.15M gross profit) to a competitor due to their broader banking relationship requirements, not service quality.
• Regulatory Uncertainty: Timeline for Aferion FDA approval remains undefined; delays could impact commercial launch timing.
• Program Onboarding Timing: Heavy reliance on H2 onboarding (specifically around Asymbia conference in April and Jan 1st insurance resets) creates front-loaded seasonality risks if H1 growth does not accelerate.
• Banking Partnerships: Potential for future churn of plasma centers if their primary banking partners exit the relationship.

Management Tone on the Future:

• Confidence Level: High. Management states they are "raising projections" on key metrics despite the plasma transition, citing "confidence in the long-term earnings power of the platform."
• Strategic Validation: Describes the strategy as "working" with "operating leverage" and "margin expansion."
• Future Outlook: Confident in delivering "strong, meaningful, year-over-year, top-and-bottom-line growth for the foreseeable future."

Miscellaneous:

• Replay Availability: Earnings call replay available until January 25, 2027.
• Share Count: Fully diluted share count was 62.7 million in Q3 2026 vs. 61.8 million in Q3 2025.
• Cash Position: Exited quarter with $34.5 million unrestricted cash and $201.8 million restricted cash.
• Terminology Note: Transcript contains recurring references to "Ethereum software platform" (e.g., "Ethereum software platform is actually going to help..."), which appears to be an error for "Aferion" based on context of plasma software and regulatory review.